Clinical trials: Giant Cells Arteritis
Giant Cell Arteritis
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Primary Objective: To evaluate the efficacy of sarilumab in participants with giant cell arteritis (GCA) as assessed by the proportion of participants with sustained remission for sarilumab compared to placebo, in combination…
- Trial name
- NCT03600805
- Testing
- Sarilumab SAR153191, Prednisone
- Where
- 61 sites in United States, Argentina and 19 more
- Volunteers
- 83 people
- Sponsor
- Sanofi
COVID-19, Systemic Lupus Erythematosus
Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe
The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern.
- Conditions
- COVID-19, Systemic Lupus Erythematosus, Sjogren's Syndrome, Axial Spondyloarthritis
- Trial name
- Euro-COVIMID (NCT04397237)
- Where
- France
- Volunteers
- 3,100 people
- Sponsor
- Pitié-Salpêtrière Hospital
Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis
This prospective study is to explore different predictive factors for response to steroid treatment in patients with PMR and/or GCA.
- Trial name
- NCT05479448
- Testing
- Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness), Data collection for exploratory analyses of endogenous steroid hormones, Data collection for correlation between clinical defined and lab defined GC responsivness
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
Giant Cell Arteritis, Acute Phase
Study of Circulating Microparticles in Giant Cell Arteritis
To demonstrate that microparticles (MPs), having a powerful procoagulant potential, are in larger amounts in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex…
- Trial name
- MicroGiant (NCT02333708)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.
- Conditions
- Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis, Takayasu Arteritis, Giant Cell Arteritis
- Trial name
- NAREG (NCT05904301)
- Testing
- Usual medical management of patients, additional blood and stool samples for biobanking
- Where
- 6 sites in Armenia
- Volunteers
- 800 people
- Sponsor
- Santé Arménie French-Armenian Research Center
Rheumatic Diseases, Rheumatoid Arthritis (RA)
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases.
- Conditions
- Rheumatic Diseases, Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA), Psoriatic Arthritis (PsA)
- Trial name
- CARe RAiSE (NCT07150000)
- Testing
- Ex Vivo Assay
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)
Polymyalgia rheumatica (PMR) is a rheumatologic condition occurring in patients > 50 years old, characterized by inflammatory pain of the scapular (shoulder) and pelvic (hip) girdles.
- Trial name
- THROPIQ (NCT06609668)
- Testing
- Additional blood samples
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis (GCA)
oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound
The purpose of this study is to evaluate whether the measure of the optic nerve sheath is a reliable diagnostic marker for giant cell arteritis
- Trial name
- PETRUS (NCT07001059)
- Testing
- orbital ultrasound
- Where
- 9 sites in France
- Volunteers
- 190 people
- Sponsor
- Hôpital NOVO
Giant Cell Arteritis, Polymyalgia Rheumatica
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
The GCAIO study is an innovative, multimodal research initiative designed to enhance the understanding, diagnosis, and management of giant cell arteritis (GCA) and frequently associated polymyalgia rheumatica (PMR).
- Trial name
- GCAIO (NCT06460142)
- Testing
- Aortic/ cardiac magnetic resonance imaging, Vascular ultrasound, Transorbital Ultrasound
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Giant Cell Arteritis
Giant Cell Arteritis and PET Scan (GAPS) Study
Giant cell arteritis (GCA) is a medium to large vessel vasculitis with a predilection for the superficial cranial and intrathoracic arteries.
- Trial name
- NCT02771483
- Where
- Australia
- Volunteers
- 64 people
- Sponsor
- Royal North Shore Hospital
Rheumatic Diseases, Adult Onset Still Disease
Rheumatology Patient Registry and Biorepository
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
- Conditions
- Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT04402086
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Yale University
Rheumatoid Arthritis, Giant Cell Arteritis
Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers
A single dose, two period trial where participants will be given either of 3 Tocilizumab product on Day 1 during period 1 and either one of the remaining 2 Tocilizumab products on Day 1 period 2.
- Trial name
- NCT04885829
- Testing
- Tocilizumab Prefilled Syringe
- Where
- 4 sites in Australia, India and 1 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Adrenal Insufficiency, Polymyalgia Rheumatica
Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
In this double-blinded randomised placebo-controlled clinical trial, the aim is to determine the effect of supplemental hydrocortisone compared with placebo during mild to moderate physical or mental stress on health related…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica, Giant Cell Arteritis
- Trial name
- RESCUE (NCT05435781)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 250 people
- Sponsor
- Marianne Christina Klose
Giant Cell Arteritis
Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)
The aim of this study is to compare the use of FDG PET/CT to Ga-68 HA-DOTATATE (abbreviated DOTATATE) PET/CT in patients with active giant cell arteritis (GCA) started on prednisone to understand if DOTATATE can identify more…
- Trial name
- NCT03812302
- Testing
- 68-Ga HA-DOTATATE PET/CT
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University of Alberta
Giant Cell Arteritis, Takayasu Arteritis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Vasculitis occur when the body's immune system, rather than protecting the body, attacks blood vessels, causing injury to the vessel and the part of the body it supplies with blood.
- Conditions
- Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis
- Trial name
- BIOVAS (NCT05168475)
- Testing
- Rituximab, Infliximab, Tocilizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Giant Cell Arteritis
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
The purpose of this study is to demonstrate the efficacy and safety of subcutaneously (s.c.) administered secukinumab 300 mg in combination with glucocorticoid taper regimen compared to placebo in combination with glucocorticoid…
- Trial name
- GigAINt (NCT05380453)
- Testing
- Secukinumab 300 mg, s.c.
- Where
- 25 sites in Germany
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis, Polymyalgia Rheumatica
Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.
The goal of this observational study is to expand the knowledge about development and aggreviation of diabetes mellitus in patients with giant cell arthritis and polymyalgia rheumatica.
- Conditions
- Giant Cell Arteritis, Polymyalgia Rheumatica, Large Vessel Vasculitis
- Trial name
- NCT06011512
- Where
- Denmark
- Volunteers
- 198 people
- Sponsor
- Salome Kristensen
Temporal Arteritis
Aetiology of TemporaL Arteritis Study
Giant Cell Arteritis (GCA) is the most common vasculitis and has significant morbidity in terms of blindness, stroke, and tissue necrosis.
- Trial name
- ATLAS (NCT02584517)
- Sponsor
- University of Oxford
Chronic Coronary Syndrome, Heart Failure
COVID-19 Related Lockdown Effects On Chronic Diseases
The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation.
- Conditions
- Chronic Coronary Syndrome, Heart Failure, AMD and Macular Edema, Chronic Respiratory Failure
- Trial name
- CLEO-CD (NCT04390126)
- Testing
- life questionnaires, questionnaire
- Where
- France
- Volunteers
- 1,343 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Horton's Disease, Infectious Disease
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease.
- Conditions
- Horton's Disease, Infectious Disease, Neoplasia, Solid Tumor
- Trial name
- NCT02065297
- Testing
- 1 blood sample, 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
- Where
- 3 sites in France
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon